Skip to main content
. Author manuscript; available in PMC: 2013 Jul 1.
Published in final edited form as: Nucl Med Biol. 2012 Feb 10;39(5):645–651. doi: 10.1016/j.nucmedbio.2011.12.001

Fig 3.

Fig 3

Histograms presenting the target to non-target ratios for pretargeting using MORF-HPi1 and 111In labeled cMORF and for direct targeting using 111In labeled HPi1. Between pretargeting and direct targeting, P <0.05 for all organs except for muscle at 10 h (P=0.06)